[Results of immunotherapy with HDM (Bencard) in children with bronchial asthma].
Desensitization with HDM manufactured by Bencard was carried out in a group of 20 children with bronchial asthma showing hypersensitivity to Dermatophagoides pteronyssimus allergen in prick skin tests. Ten randomly selected children treated symptomatically and with climate served as a control group. Children were examined clinically before and after desensitization. Clinical improvement was observed 15 months after desensitization together with weakened delayed bronchial response to allergen inhalation. No significant difference in patency of airway was seen in both groups. Differences in serum IgE and IgG levels and mean eosinophilia in the peripheral blood were statistically insignificant.
Matoga
S
S
Sciślicki
A
A
Hałuszka
J
J
Kurzawa
R
R
D001205:Ascorbic Acid / Q000627:therapeutic use*; D001249:Asthma / Q000503:physiopathology / Q000628:therapy*; D002648:Child; D003888:Desensitization, Immunologic; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007073:Immunoglobulin E / Q000378:metabolism; D007074:Immunoglobulin G / Q000378:metabolism; D008297:Male; D012123:Pulmonary Ventilation; D014803:Vitamin B Complex / Q000627:therapeutic use*
D004338:Drug Combinations; D007074:Immunoglobulin G; D014803:Vitamin B Complex; D007073:Immunoglobulin E; C054937:parentrovite; D001205:Ascorbic Acid
Wyniki immunoterapii preparatem hdm (bencard) u dzieci chorych na dycahawice oskrzelowa.